Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma
-
Published:2021-02
Issue:
Volume:144
Page:182-191
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Robert Caroline, Hwu Wen-JenORCID, Hamid OmidORCID, Ribas Antoni, Weber Jeffrey S., Daud Adil I., Hodi F. Stephen, Wolchok Jedd D., Mitchell Tara C., Hersey PeterORCID, Dronca Roxana, Joseph Richard W., Boutros Celine, Min Le, Long Georgina V.ORCID, Schachter Jacob, Puzanov Igor, Dummer Reinhard, Lin Jianxin, Ibrahim Nageatte, Diede Scott J., Carlino Matteo S., Joshua Anthony M.
Funder
Merck Sharp and Dohme
Subject
Cancer Research,Oncology
Reference24 articles.
1. Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis;Karlsson;Clin Cosmet Invest Dermatol,2017 2. KEYTRUDA® (pembrolizumab) for injection, for intravenous use. 11/2020,2020 3. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001;Hamid;Ann Oncol,2019 4. Final analysis of a randomized trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma;Hamid;Eur J Canc,2017 5. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study;Robert;Lancet Oncol,2019
Cited by
64 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|